A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

Trial Profile

A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms NURTURE
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov (Parent trial: NCT00899678).
    • 14 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov (Parent trial: NCT00899678).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top